Topic

Articles

The companies will work to accelerate the clinical development and manufacturing of the treatment, while determining its safety and efficacy.

Roche and Atea Pharmaceuticals Collaborate on Investigational Oral Antiviral for COVID-19

Orgenesis has completed its previously announced acquisition of Koligo Therapeutics with the additional acquisition of Tissue Genesis’ cell isolation technology, Icellator.  

Orgenesis Completes Koligo Acquisition and Gains Icellator Technology in Related Transaction

Roche will use Dyno’s CapsidMap platform to develop next-generation adeno-associated virus vectors for gene therapies for central nervous system diseases and liver-directed therapies. 

Roche and Dyno Therapeutics to Enter into $1.8 Billion Collaboration 

The company will supply its LIMS to the Walter Reed Army Institute of Research (WRAIR) to support vaccine production programs for COVID-19 at WRAIR’s pilot bioproduction facility.

LabVantage Awarded US Army Contract for LIMS COVID-19 Vaccine Support

The companies are entering into an agreement for the late-stage development and large-scale manufacturing of AZD7442, AstraZeneca’s investigational product for treatment and prevention of COVID-19.

HHS, DoD, AstraZeneca Enter into $486-Million Agreement for COVID-19 Investigational Product

Rentschler will handle the downstream processing to provide highly purified drug substance at its headquarters in Laupheim, Germany.

Rentschler to Partner with BioNTech for COVID-19 Vaccine Manufacturing 

The partnership aims to provide a platform of hiPSC-based assays, drug discovery technologies, high-throughput screening, and high-content screening.

Fujifilm Cellular Dynamics and Axxam Team Up for Drug Discovery Platform 

Under the contract, Pharm-Olam will offer routine and response clinical services for the development of medical countermeasures.

Pharm-Olam Selected to Join BARDA’s Clinical Studies Network

Through the acquisition, Bristol Myers Squibb will gain access to MyoKardia’s mavacamten, a cardiovascular drug for the treatment of obstructive hypertrophic cardiomyopathy, a chronic heart disease.



Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion

The acquisition will support the accelerated commercialization of Kyslecel (autologous pancreatic islets), Koligo’s personalized cell therapy for treating pancreatitis.

Deals, Development and Manufacturing